Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | MAP3K12 | Q12852 | 8/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16985571 | 1.00 | LRRK2 (0.37) | LRRK2KCNH2MAP3K12DYRK1AKAT2B | |
| SCHEMBL21850266 | 1.00 | LRRK2 (0.37) | LRRK2KCNH2MAP3K12DYRK1AKAT2B | |
| SCHEMBL21087663 | 0.88 | LRRK2 (0.44) | LRRK2KCNH2MAP3K12KAT2B | |
| SCHEMBL18387646 | 0.85 | LRRK2 (0.33) | LRRK2KCNH2MAP3K12 | |
| SCHEMBL21851561 | 0.81 | LRRK2 (0.36) | LRRK2KCNH2DYRK1AKAT2B | |
| SCHEMBL5021297 | 0.80 | LRRK2 (0.39) | LRRK2KCNH2MAP3K12KAT2B | |
| SCHEMBL16985567 | 0.80 | LRRK2 (0.35) | LRRK2KCNH2KAT2B | |
| SCHEMBL16985550 | 0.80 | LRRK2 (0.35) | LRRK2KCNH2KAT2B | |
| SCHEMBL21850251 | 0.77 | LRRK2 (0.47) | LRRK2KCNH2MAP3K12KAT2B | |
| SCHEMBL16985407 | 0.75 | LRRK2 (0.53) | LRRK2KCNH2MAP3K12DYRK1AKAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-14 | — | — | US | disclosed |
| EP-3099695-B1 | COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-04-08 | — | — | EP | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| WO-2015113452-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | LRRK2, PARK7, PINK1 | LRRK2 1/4885KCNH2 3594/4885MAP3K12 118/4885 |
| US-20170015668-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | LRRK2 1/4885KCNH2 3477/4885MAP3K12 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.